BioLineRx (NASDAQ:BLRX – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.14), MarketWatch Earnings reports. During the same period in the prior year, the firm earned ($0.16) EPS.
BioLineRx Trading Up 2.9 %
Shares of BLRX stock opened at $1.43 on Thursday. The business’s 50 day moving average is $1.52 and its two-hundred day moving average is $1.24. BioLineRx has a twelve month low of $0.55 and a twelve month high of $1.82. The company has a market capitalization of $87.99 million, a P/E ratio of -2.53 and a beta of 1.84. The company has a current ratio of 3.68, a quick ratio of 3.68 and a debt-to-equity ratio of 0.21.
Institutional Trading of BioLineRx
Several hedge funds and other institutional investors have recently made changes to their positions in the company. LPL Financial LLC boosted its holdings in shares of BioLineRx by 6.4% in the second quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 7,500 shares in the last quarter. Envestnet Asset Management Inc. purchased a new stake in shares of BioLineRx in the first quarter valued at approximately $88,000. Renaissance Technologies LLC boosted its stake in shares of BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 189,678 shares in the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of BioLineRx in the first quarter valued at approximately $178,000. Hedge funds and other institutional investors own 2.01% of the company’s stock.
Wall Street Analysts Forecast Growth
BioLineRx Company Profile
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Five stocks we like better than BioLineRx
- There Are Different Types of Stock To Invest In
- This is How Salesforce.com Gets Back to its All-Time High
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Online Retailers To Revamp Your Shopping List With
- Investing In Automotive Stocks
- 3 Bitcoin Stocks To Watch Following Grayscale’s Legal Victory
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.